Pricing Log in Create free account

Arvinas, Inc. (ARVN) vs Monopar Therapeutics Inc. (MNPR)

Arvinas, Inc. and Monopar Therapeutics Inc. are both Biotechnology companies. Arvinas, Inc. and Monopar Therapeutics Inc. are of similar size ($481.9M and $468.2M). Monopar Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Arvinas, Inc. trades at 53.6×. Arvinas, Inc. has the higher net margin (2.94% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Arvinas, Inc. leads on 7 and Monopar Therapeutics Inc. on 5.

Valuation

Metric ARVN MNPR Biotechnology median
P/E 53.62 n/m 8.50
P/S 1.43 n/m 9.71
P/B 0.80 4.52 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 6.41 n/m 0.64
EV/Sales (0.36) n/m 9.21
Earnings yield 1.87% (3.13%) (33.15%)
Free cash flow yield (46.23%) (2.06%) (25.50%)

Profitability

Metric ARVN MNPR Biotechnology median
Gross margin 97.16% — 65.16%
Operating margin (5.72%) 0.00% 0.00%
Net margin 2.94% 0.00% 0.00%
Free cash flow margin (65.93%) 0.00% 0.00%
Return on equity 1.59% (19.50%) (56.36%)
Return on assets 1.17% (18.90%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARVN MNPR Biotechnology median
Revenue growth (TTM) (15.05%) — 6.02%
EPS growth (last fiscal year) 58.84% 54.99% 30.26%
Revenue growth, 5-year CAGR 58.93% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARVN MNPR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.91 33.56 4.72
Net debt to EBITDA 5.62 8.06 0.96

Dividend

Metric ARVN MNPR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ARVN MNPR Biotechnology median
Market cap 468.16m 481.93m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack